CMS

CMS delays clinical lab fee schedule data reporting, cuts capped at 15% for 2021
CMS delays clinical lab fee schedule data reporting, cuts capped at 15% for 2021
Medtech Dive
CMS
devices
diagnostics
clinical laboratory fees
Flag link:
Latest CMS Data: Drug Spending is Not Skyrocketing; Hospitals and Physicians Dominate Healthcare Costs
Latest CMS Data: Drug Spending is Not Skyrocketing; Hospitals and Physicians Dominate Healthcare Costs
Drug Channels
CMS
drug spending
hospitals
Flag link:
CMS proposes lifting restrictions on NGS cancer testing
CMS proposes lifting restrictions on NGS cancer testing
Biopharma Dive
CMS
next generation sequencing
diagnostics
oncology
cancer
Medicare
Flag link:
Preferred Pharmacy Networks Rebound in 2020 Medicare Part D Plans: Details on WellCare, CVS Health, Humana, Cigna, and More
Preferred Pharmacy Networks Rebound in 2020 Medicare Part D Plans: Details on WellCare, CVS Health, Humana, Cigna, and More
Drug Channels
CMS
Medicare
Medicare Part D
preferred pharmacy networks
Flag link:
CMS to cover CAR-T therapy nationwide
CMS to cover CAR-T therapy nationwide
Beckers Hospital Review
Medicare
CMS
CAR-T
Flag link:
CMS prescribes payment fix to resuscitate US antibiotic industry
CMS prescribes payment fix to resuscitate US antibiotic industry
Endpoints
CMS
antibiotics
drug development
Flag link:
Pharma shells out $3B to doctors and hospitals—with Roche, Sanofi leading: CMS
Pharma shells out $3B to doctors and hospitals—with Roche, Sanofi leading: CMS
Fierce Pharma
CMS
hopsitals
physicians
physician payments
Flag link:
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
CMS approves Louisiana's 'Netflix model' with Gilead for hepatitis C drugs
Biopharma Dive
hepatitis C
Medicaid
Netflix model
Louisiana
Gilead Sciences
CMS
Flag link:
Federal Court Punts Regarding Remedy Related to CMS’ Invalidated Rule Concerning Medicare Hospital Outpatient Payment Rates for 340B Drugs
Federal Court Punts Regarding Remedy Related to CMS’ Invalidated Rule Concerning Medicare Hospital Outpatient Payment Rates for 340B Drugs
FDA Law Blog
FDA
CMS
Medicare
340B
Flag link:
CMS reopens coverage determination on next-gen sequencing for cancer patients
CMS reopens coverage determination on next-gen sequencing for cancer patients
Medtech Dive
CMS
Medicare
next generation sequencing
cancer
Flag link:
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
Motley Fool
Gilead Sciences
Novartis
CMS
Medicare
CAR-T
Flag link:
Medicare proposes raising CAR-T pay, but reimbursement solution years away
Medicare proposes raising CAR-T pay, but reimbursement solution years away
Biopharma Dive
CMS
CAR-T
Medicare
reimbursement
Flag link:
CMS demo could pave the path to eliminating Part D rebates
CMS demo could pave the path to eliminating Part D rebates
BioCentury
CMS
drug pricing
Medicare Part D
drug rebates
Flag link:
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Electronic Health Records: A Promising New Way To Fight the Opioid Epidemic
Forbes
opioids
opioid crisis
EHRs
EMRs
CMS
Flag link:
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Drug spending could rise 6.1 percent annually by 2020, federal projections show
Stat
drug spending
CMS
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Governor moves to boost California's drug price bargaining power
Governor moves to boost California's drug price bargaining power
BioCentury
drug pricing
CMS
Medicaid
California
Flag link:
CMS rule cuts reimbursement for new Part B drugs
CMS rule cuts reimbursement for new Part B drugs
BioCentury
Medicare Part B
CMS
reimbursement
physician-administered drugs
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Medtech reporting would change under new opioid law
Medtech reporting would change under new opioid law
Mass Device
opioids
opioid crisis
Medicare
Medicaid
CMS
devices
Flag link:

Pages